Theraclion: 95% Vein Occlusion Rate: Results Presented by Dr Stalnikiewicz at the Swiss Vein Days 2022
21 Juni 2022 - 6:00PM
Business Wire
Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE),
an innovative company developing a scalable robotic platform for
non-invasive ultrasound therapy, announces today the
presentation of echotherapy treatment results by Dr Stalnikiewicz
at Swiss Vein Days 2022. The Lille-based expert achieved a 95% vein
occlusion rate for all his patients since the end of his learning
curve, thanks to the advanced non-invasive SONOVEIN®
technology.
One of the world’s first echotherapy experts for varicose
veins
For the first time, Dr Guillaume Stalnikiewicz, practising in
Wambrechies (Lille) and president of NordPhlebo, presented his
results to a scientific audience. Since the first patient in March
2020, the phlebologist has treated 35 GSV (‘great saphenous vein’),
38 perforating veins, 5 LLG (‘neo-saphenous veins’), 6 SSV (‘small
saphenous veins’) et 5 ASV (‘accessory saphenous vein’), i.e. a
total of 85 patients and 89 veins. After a learning period, Dr
Stalnikiewicz achieved a 95% occlusion rate for all veins. The ages
of the patients treated range from 33 to 88 years old. These
patients corresponded to SONOVEIN® S use instructions.
A treatment with results equivalent to endovenous
methods
At the Swiss Vein Days on June 9th and 10th 2022 in Bruderholz,
Switzerland, Dr Stalnikiewicz expressed his satisfaction with the
high intensity focused ultrasound (HIFU) treatment system: ‘I am
particularly pleased to be able to present these results, because
they are very close to the ones I have achieved with existing
endovenous methods. The significant advantage, for both patient and
doctor, is that echotherapy is non-invasive and allowed us to treat
cases impossible to treat with traditional thermal methods’.
Theraclion’s general director David Caumartin welcomed the
collaboration with the Lille-based doctor, one of the very first to
be trained in echotherapy for varicose veins, and sees it as a
strong signal for the development of the technology: ‘The
presentation of these results is an important confirmation of the
effectiveness of our latest SONOVEIN® HD robotic platform’.
About Theraclion
At Theraclion we believe that surgery, as we know it, is
outdated. It converts optimistic patients into anxious individuals,
brilliant doctors into exhausted system executors and stretches
healthcare systems to the limit. We have disrupted this convention
by creating extracorporeal treatment platforms. We replace surgery
with a robotic treatment from outside the body using High Intensity
Focused Ultrasound (HIFU). Our leading edge echotherapy platforms
are currently CE marked in non-invasive treatment of varicose veins
with SONOVEIN® and of breast fibroadenomas and thyroid nodules with
Echopulse®.
Located in Malakoff, near Paris, our employees live and breathe
innovation by extensive clinical research and harness artificial
intelligence. The market of varicose veins treatment alone requires
around 5 million procedures annually. It is a dynamic market in
which we change paradigms by making non-invasive echotherapy the
new standard.
For more information, please visit
www.theraclion.com and our patient website
www.echotherapy.com.
Theraclion is listed on Euronext Growth Paris
Eligible for the PEA-PME scheme
Mnemonic: ALTHE - ISIN code: FR0010120402
LEI: 9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621005746/en/
Theraclion David AUREGAN Chief Operating Officer
david.auregan@theraclion.com
Anja KLEBER VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com
Theraclion (EU:ALTHE)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Theraclion (EU:ALTHE)
Historical Stock Chart
Von Apr 2023 bis Apr 2024